- Email: [email protected]
5112749 Vaccines for the malaria circumsporozoite protein
xii
New Patents
Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both live and inactivated are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.
5110910 VIRUCIDAL EUGLOBULIN PRECIPITATION Grace C Tsav assigned to Miles Inc A source for antibodies (both IgG and IgM types) is put into an aqueous solution which includes a virucidal agent under conditions sufficient to assure substantially complete dissolution of both the antibodies and the virucidal agent and virus inactivation. Then the pH, conductivity and antibody concentration of the solution are then changed to obtain conditions sufficient to assure the precipitation of substantially all antibodies while maintaining substantially all of the virucidal agent in the supernatant solution. In preferred embodiments, using a TNBP/TWEEN virucidal agent, the original solution conductivity ranges from about 0.03 to 0.20 M MHO/CM, the pH ranges from about 4.75 to 4.85, and the protein concentration, when measured at A280, ranges from a reading of about 5 to 40. In the second precinitation step, the pH is changed to a range of about 6.0 to 7.5 and the conductivity is changed to a range of about 0.05 to 0.70 M MHO/CM to achieve an IgM precipitation ranging from about 30 to 80% by weight total protein.
5112735 DETECTION OF LYMPHOCYTE AMPLIFICATION Richard J Albertini assigned to University of Vermont A method for detecting lymphocyte clonal amplification in a mammal by cloning of lymphocytes so as to identify cell lines expressing a mutation at a structural locus and determining the structure of the antigen receptor in the mutated clonal cell lines. Similar rearrangements of the regions of nucleic acid encoding antigen receptor among multiple isolated clones from a single individual indicate an in vivo clonal lymphocyte amplification event.
5112749 VACCINES FOR THE MALARIA CIRCUMSPOROZOITE PROTEIN Robert N Brey, William R Majarian, Subramoni Pillai, Wayne T Hockmeyer assigned to Praxis Biologics Inc The present invention is directed to attenuated strains of enteroinvasive bacteria that express a peptide or protein related to an epitope of the malaria parasites of the genus Plasmodium. The bacterial strains of the invention which can multiply in a host without causing significant disease or disorder, and which express a Plasmodium-related peptide that induces a protective immune response against malaria, can be used in live vaccine formulations for malaria. In specific embodiments, a Plasmodium-related peptide can be expressed as a fusion protein, for example, with a bacterial enterotoxin. The invention also relates to methods for expression of malaria antigens or fragments thereof within attenuated enteroinvasive bacteria. In particular embodiments, the invention is directed to the expression by attenuated Salmonella spp. of epitopes of Plasmodium circumsporozoite proteins.
5112756 CONTINUOUS PRODUCTION OF BOVINE MAEDI-VISNA-LIKE VIRAL ANTIGENS IN CF2TH CELLS Alain M P Bouillant, Klaus Nielsen, Gerda M Ruckerbauer, Bakhshish S Samagh, William C D Hare, Aylmer, Canada assigned to Canadian Patents and Development Limited
New Patents
Peptides and proteins related to an epitope comprising an outer membrane protein of Haemophilus influenzae are described. The peptides and proteins can be prepared by methods including novel and improved methods of puiification from H. influenzae cultures, and by recombinant DNA and chemical synthetic techniques. Additionally, recombinant vectors containing nucleotide sequences encoding PBOMP1 and PBOMP-2 related peptides and proteins are also described. Recombinant vectors include plasmid DNA and viral DNA such as human viruses, animal viruses, insect viruses and bacteriophages that direct the expression of the PBOMP-1 and PBOMP-2 related peptides and proteins in appropriate host cells. The peptides, proteins and viruses both live and inactivated are used as immunogens in vaccine formulations to protect against H. influenzae infections. The peptides and proteins are also used as reagents in immunoassays as well as to prepare immunoglobulins for passive immunization. Use of the nucleotide sequences encoding the PBOMP related peptides and proteins in hybridization assays is also described.
5110910 VIRUCIDAL EUGLOBULIN PRECIPITATION Grace C Tsav assigned to Miles Inc A source for antibodies (both IgG and IgM types) is put into an aqueous solution which includes a virucidal agent under conditions sufficient to assure substantially complete dissolution of both the antibodies and the virucidal agent and virus inactivation. Then the pH, conductivity and antibody concentration of the solution are then changed to obtain conditions sufficient to assure the precipitation of substantially all antibodies while maintaining substantially all of the virucidal agent in the supernatant solution. In preferred embodiments, using a TNBP/TWEEN virucidal agent, the original solution conductivity ranges from about 0.03 to 0.20 M MHO/CM, the pH ranges from about 4.75 to 4.85, and the protein concentration, when measured at A280, ranges from a reading of about 5 to 40. In the second precinitation step, the pH is changed to a range of about 6.0 to 7.5 and the conductivity is changed to a range of about 0.05 to 0.70 M MHO/CM to achieve an IgM precipitation ranging from about 30 to 80% by weight total protein.
5112735 DETECTION OF LYMPHOCYTE AMPLIFICATION Richard J Albertini assigned to University of Vermont A method for detecting lymphocyte clonal amplification in a mammal by cloning of lymphocytes so as to identify cell lines expressing a mutation at a structural locus and determining the structure of the antigen receptor in the mutated clonal cell lines. Similar rearrangements of the regions of nucleic acid encoding antigen receptor among multiple isolated clones from a single individual indicate an in vivo clonal lymphocyte amplification event.
5112749 VACCINES FOR THE MALARIA CIRCUMSPOROZOITE PROTEIN Robert N Brey, William R Majarian, Subramoni Pillai, Wayne T Hockmeyer assigned to Praxis Biologics Inc The present invention is directed to attenuated strains of enteroinvasive bacteria that express a peptide or protein related to an epitope of the malaria parasites of the genus Plasmodium. The bacterial strains of the invention which can multiply in a host without causing significant disease or disorder, and which express a Plasmodium-related peptide that induces a protective immune response against malaria, can be used in live vaccine formulations for malaria. In specific embodiments, a Plasmodium-related peptide can be expressed as a fusion protein, for example, with a bacterial enterotoxin. The invention also relates to methods for expression of malaria antigens or fragments thereof within attenuated enteroinvasive bacteria. In particular embodiments, the invention is directed to the expression by attenuated Salmonella spp. of epitopes of Plasmodium circumsporozoite proteins.
5112756 CONTINUOUS PRODUCTION OF BOVINE MAEDI-VISNA-LIKE VIRAL ANTIGENS IN CF2TH CELLS Alain M P Bouillant, Klaus Nielsen, Gerda M Ruckerbauer, Bakhshish S Samagh, William C D Hare, Aylmer, Canada assigned to Canadian Patents and Development Limited